Targeting Protein Modification: a New Direction for Immunotherapy of Pancreatic Cancer

Overview

Journal Int J Biol Sci

Specialty Biology

Date 2025 Jan 2

PMID 39744438

Authors

Xinyu Ge

Ke Zhang

Jie Zhu

Yuan Chen

Zhengwang Wang

Peng Wang

Peng Xu

Jie Yao

Affiliations

Soon will be listed here.

Abstract

Post-translational modifications (PTMs) alter protein conformation by covalently attaching functional groups to substrates, influencing their biological activity, mechanisms of action, and functional performance. PTMs and their interactions are essential to many critical signal transduction processes, including tumor transformation, cancer progression, and metastasis in pancreatic cancer. Additionally, advancements in tumor immunotherapy indicate that PTMs are essential in immune cell activation, transport, and energy metabolism. This study aimed to investigate the effects of different PTMs on immunotherapy for pancreatic cancer, providing new perspectives and suggesting directions for future research.

References

Nelson J, Zaw Thin M, Evan T, Howell S, Wu M, Almeida B . USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer. Nat Commun. 2022; 13(1):2070. PMC: 9018856. DOI: 10.1038/s41467-022-29684-9. View

Costa A, Campos D, Reis C, Gomes C . Targeting Glycosylation: A New Road for Cancer Drug Discovery. Trends Cancer. 2020; 6(9):757-766. DOI: 10.1016/j.trecan.2020.04.002. View

Wu X, Xu M, Geng M, Chen S, Little P, Xu S . Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies. Signal Transduct Target Ther. 2023; 8(1):220. PMC: 10224996. DOI: 10.1038/s41392-023-01439-y. View

Alam M, Gaida M, Ogawa Y, Kolios A, Lasitschka F, Ashwell J . Counter-regulation of T cell effector function by differentially activated p38. J Exp Med. 2014; 211(6):1257-70. PMC: 4042639. DOI: 10.1084/jem.20131917. View

Shi L, Tu B . Acetyl-CoA and the regulation of metabolism: mechanisms and consequences. Curr Opin Cell Biol. 2015; 33:125-31. PMC: 4380630. DOI: 10.1016/j.ceb.2015.02.003. View

Wan J, Liu H, Chu J, Zhang H . Functions and mechanisms of lysine crotonylation. J Cell Mol Med. 2019; 23(11):7163-7169. PMC: 6815811. DOI: 10.1111/jcmm.14650. View

Feng C, Zhang L, Chang X, Qin D, Zhang T . Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy. Front Immunol. 2023; 14():1230135. PMC: 10405826. DOI: 10.3389/fimmu.2023.1230135. View

Kruusmagi M, Zelenin S, Brismar H, Scott L . Intracellular dynamics of calcyon, a neuron-specific vesicular protein. Neuroreport. 2007; 18(15):1547-51. DOI: 10.1097/WNR.0b013e3282f03f51. View

Steele C, Karim S, Leach J, Bailey P, Upstill-Goddard R, Rishi L . CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2016; 29(6):832-845. PMC: 4912354. DOI: 10.1016/j.ccell.2016.04.014. View

10.

Wang Y, Sun Q, Mu N, Sun X, Wang Y, Fan S . The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells. Cell Commun Signal. 2020; 18(1):112. PMC: 7362500. DOI: 10.1186/s12964-020-00612-y. View

11.

Kim E, Liu P, Zhang S, Donahue K, Wang Y, Schehr J . BAF155 methylation drives metastasis by hijacking super-enhancers and subverting anti-tumor immunity. Nucleic Acids Res. 2021; 49(21):12211-12233. PMC: 8643633. DOI: 10.1093/nar/gkab1122. View

12.

Kaur S, Kumar S, Momi N, Sasson A, Batra S . Mucins in pancreatic cancer and its microenvironment. Nat Rev Gastroenterol Hepatol. 2013; 10(10):607-20. PMC: 3934431. DOI: 10.1038/nrgastro.2013.120. View

13.

Prokakis E, Bamahmoud H, Jansari S, Fritsche L, Dietz A, Boshnakovska A . USP22 supports the aggressive behavior of basal-like breast cancer by stimulating cellular respiration. Cell Commun Signal. 2024; 22(1):120. PMC: 10863169. DOI: 10.1186/s12964-023-01441-5. View

14.

Xie X, Zhou Y, Wang X, Guo J, Li J, Fan H . Enhanced antitumor activity of gemcitabine by polysaccharide-induced NK cell activation and immune cytotoxicity reduction in vitro/vivo. Carbohydr Polym. 2017; 173:360-371. DOI: 10.1016/j.carbpol.2017.06.024. View

15.

Zhu Q, Zhou H, Wu L, Lai Z, Geng D, Yang W . O-GlcNAcylation promotes pancreatic tumor growth by regulating malate dehydrogenase 1. Nat Chem Biol. 2022; 18(10):1087-1095. DOI: 10.1038/s41589-022-01085-5. View

16.

Tunyasuvunakool K, Adler J, Wu Z, Green T, Zielinski M, Zidek A . Highly accurate protein structure prediction for the human proteome. Nature. 2021; 596(7873):590-596. PMC: 8387240. DOI: 10.1038/s41586-021-03828-1. View

17.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

18.

Garcia-Sanchez J, Ewbank J, Visvikis O . Ubiquitin-related processes and innate immunity in C. elegans. Cell Mol Life Sci. 2021; 78(9):4305-4333. PMC: 11072174. DOI: 10.1007/s00018-021-03787-w. View

19.

Hu T, Shukla S, Vernucci E, He C, Wang D, King R . Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression. Gastroenterology. 2021; 161(5):1584-1600. PMC: 8546779. DOI: 10.1053/j.gastro.2021.06.045. View

20.

Jeong M, Urquhart G, Lewis C, Chi Z, Jewell J . Inhibition of phosphodiesterase 4D suppresses mTORC1 signaling and pancreatic cancer growth. JCI Insight. 2023; 8(13). PMC: 10371348. DOI: 10.1172/jci.insight.158098. View